Literature DB >> 7862925

m-Chlorophenylpiperazine decreases food intake in a test meal.

A E Walsh1, K A Smith, A D Oldman, C Williams, E M Goodall, P J Cowen.   

Abstract

We studied the effect of the 5-HT receptor agonist, m-chlorophenylpiperazine (mCPP) (0.4 mg/kg), on food intake in 12 healthy female volunteers, in a double-blind placebo controlled design. Compared to placebo, mCPP significantly lowered food intake in a test meal. Treatment with mCPP also caused significant increases in ratings of nausea and light-headedness, though these effects had remitted by the time of the test meal. The results suggest that activation of brain 5-HT2C receptors may lower food intake in humans; it is also possible, however, that the hypophagic effect of mCPP in the present study could be a consequence of its adverse subjective side effects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7862925     DOI: 10.1007/bf02244883

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  12 in total

1.  Disposition and pharmacological effects of m-Chlorophenylpiperazine in rats.

Authors:  R W Fuller; H D Snoddy; N R Mason; J E Owen
Journal:  Neuropharmacology       Date:  1981-02       Impact factor: 5.250

2.  Effect of acute tryptophan depletion on mood and appetite in healthy female volunteers.

Authors:  A D Oldman; A E Walsh; P Salkovskis; D A Laver; P J Cowen
Journal:  J Psychopharmacol       Date:  1994-01       Impact factor: 4.153

3.  Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers.

Authors:  E M Goodall; P J Cowen; M Franklin; T Silverstone
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  Carbohydrate craving, obesity and brain serotonin.

Authors:  R J Wurtman; J J Wurtman
Journal:  Appetite       Date:  1986       Impact factor: 3.868

Review 5.  Is there a role for serotonin (5-hydroxytryptamine) in feeding?

Authors:  J E Blundell
Journal:  Int J Obes       Date:  1977

6.  Potencies of antagonists indicate that 5-HT1C receptors mediate 1-3(chlorophenyl)piperazine-induced hypophagia.

Authors:  G A Kennett; G Curzon
Journal:  Br J Pharmacol       Date:  1991-08       Impact factor: 8.739

7.  Infusion of the 5-hydroxytryptamine agonists RU24969 and TFMPP into the paraventricular nucleus of the hypothalamus causes hypophagia.

Authors:  P H Hutson; T P Donohoe; G Curzon
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

8.  The antiemetic drug trimethobenzamide prevents hypophagia due to acetyl salicylate, but not to 5-HT1B or 5-HT1C agonists.

Authors:  G A Kennett; G Curzon
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

9.  In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist.

Authors:  G A Kennett; M D Wood; A Glen; S Grewal; I Forbes; A Gadre; T P Blackburn
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

10.  Chlorophenylpiperazine: a central serotonin agonist causing powerful anorexia in rats.

Authors:  R Samanin; T Mennini; A Ferraris; C Bendotti; F Borsini; S Garattini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-08       Impact factor: 3.000

View more
  12 in total

Review 1.  Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications.

Authors:  John Dunlop; Karen L Marquis; H K Lim; Louis Leung; John Kao; Cynthia Cheesman; Sharon Rosenzweig-Lipson
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

Review 2.  Serotonergic drugs : effects on appetite expression and use for the treatment of obesity.

Authors:  Jason C G Halford; Joanne A Harrold; Emma J Boyland; Clare L Lawton; John E Blundell
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  On the behavioural specificity of hypophagia induced in male rats by mCPP, naltrexone, and their combination.

Authors:  F L Wright; R J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  2013-10-11       Impact factor: 4.530

Review 4.  Pharmacological management of appetite expression in obesity.

Authors:  Jason C G Halford; Emma J Boyland; John E Blundell; Tim C Kirkham; Joanne A Harrold
Journal:  Nat Rev Endocrinol       Date:  2010-03-16       Impact factor: 43.330

Review 5.  Serotonergic anti-obesity agents: past experience and future prospects.

Authors:  Jason C G Halford; Emma J Boyland; Clare L Lawton; John E Blundell; Joanne A Harrold
Journal:  Drugs       Date:  2011-12-03       Impact factor: 9.546

Review 6.  Lorcaserin for the treatment of obesity.

Authors:  L M Redman; E Ravussin
Journal:  Drugs Today (Barc)       Date:  2010-12       Impact factor: 2.245

Review 7.  Psychotropic drugs in the treatment of obesity: what promise?

Authors:  Jose C Appolinario; João R Bueno; Walmir Coutinho
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Aripiprazole partial agonism at 5-HT2C: a comparison of weight gain associated with aripiprazole adjunctive to antidepressants with high versus low serotonergic activities.

Authors:  Charles T Nguyen; Jennifer A Rosen; Robert G Bota
Journal:  Prim Care Companion CNS Disord       Date:  2012-10-18

9.  Investigating interactions between phentermine, dexfenfluramine, and 5-HT2C agonists, on food intake in the rat.

Authors:  Andrew J Grottick; Kevin Whelan; Erin K Sanabria; Dominic P Behan; Michael Morgan; Carleton Sage
Journal:  Psychopharmacology (Berl)       Date:  2014-12-20       Impact factor: 4.530

10.  Effects of the 5-HT2C receptor agonist meta-chlorophenylpiperazine on appetite, food intake and emotional processing in healthy volunteers.

Authors:  J M Thomas; C T Dourish; J W Tomlinson; Z Hassan-Smith; S Higgs
Journal:  Psychopharmacology (Berl)       Date:  2014-01-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.